Safety and Survival Outcomes of (177)Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior (223)Ra treatment: The RALU Study

The radium lutetium (RALU) study evaluated the feasibility of sequential α- and β-emitter use in patients with bone-predominant metastatic castration-resistant prostate cancer. Methods: This preplanned interim retrospective analysis investigated safety and survival outcomes with (177)Lu-PSMA in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahbar, Kambiz, Essler, Markus, Pabst, Kim M., Eiber, Matthias, la Fougère, Christian, Prasad, Vikas, Rassek, Philipp, Hasa, Ergela, Dittmann, Helmut, Bundschuh, Ralph A., Fendler, Wolfgang P., Kurtinecz, Milena, Schmall, Anja, Verholen, Frank, Sartor, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2023
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071785/
https://www.ncbi.nlm.nih.gov/pubmed/36302656
http://dx.doi.org/10.2967/jnumed.122.264456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071785/
https://www.ncbi.nlm.nih.gov/pubmed/36302656
http://dx.doi.org/10.2967/jnumed.122.264456

Ejemplares similares